

# Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

## Peroxidase-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG, Fc\_ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)

RRID:AB\_2338144

Type: Antibody

### Proper Citation

Jackson ImmunoResearch Labs Cat# 112-036-071, RRID:AB\_2338144

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2338144](http://antibodyregistry.org/AB_2338144)

**Proper Citation:** Jackson ImmunoResearch Labs Cat# 112-036-071, RRID:AB\_2338144

**Target Antigen:** Rat IgG, Fc? Fragment Specific

**Clonality:** unknown

**Comments:** Originating manufacturer of this product

**Antibody Name:** Peroxidase-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG, Fc\_ Fragment Specific (min X Hu,Bov,Hrs Sr Prot)

**Description:** This unknown targets Rat IgG, Fc? Fragment Specific

**Antibody ID:** AB\_2338144

**Vendor:** Jackson ImmunoResearch Labs

**Catalog Number:** 112-036-071

**Record Creation Time:** 20250819T233824+0000

**Record Last Update:** 20250820T055753+0000

### Ratings and Alerts

No rating or validation information has been found for Peroxidase-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG, Fc\_ Fragment Specific (min X Hu,Bov,Hrs Sr Prot).

No alerts have been found for Peroxidase-AffiniPure F(ab')<sub>2</sub> Fragment Goat Anti-Rat IgG, Fc\_Fragment Specific (min X Hu,Bov,Hrs Sr Prot).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Wang R, et al. (2025) Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor. Cell reports. Medicine, 6(7), 102213.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. Neoplasia (New York, N.Y.), 67, 101196.

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Molecular cancer therapeutics, 21(4), 635.